Filament Health has shipped its patented psilocybin drug candidate PEX010 to Austin Health in Melbourne for the PSI-PHY trial, the first study to combine psilocybin-assisted physiotherapy for refractory motor functional neurological disorder (FND). Sponsored by The University of Melbourne and funded by the Australian Government, this trial explores psilocybin's potential to enhance physiotherapy by modifying brain signaling to improve motor function. This marks the first use of PEX010 in a movement disorder and highlights Filament's role as a leading supplier of pharmaceutical-grade natural psilocybin. The study could open new treatment avenues for FND, a condition with no approved drug therapies.
The US-Canada trade conflict escalated as President Trump threatened to ban Canadian airplane maker Bombardier from selling in the US, citing unfair trade practices. Canada responded with retaliatory tariffs on $20 billion of US goods, including stee...
1606 Corp. has signed a non-binding Letter of Intent (LOI) with EthosEnergy O&M to manage operations and maintenance of its planned 55 MW power facility in Lufkin, Texas, aimed at supporting data centers and AI applications. EthosEnergy O&M brings ex...
abrdn Global Infrastructure Income Fund (ASGI) maintains a Hold rating due to challenges in the utility and industrial sectors causing a decline in its net asset value (NAV). The fund offers a well-covered 12% yield, but distribution coverage may wea...
Adia Med has verified it has 361 round-lot shareholders, exceeding Nasdaq Capital Market's minimum requirement of 300 for an initial listing. This milestone is part of Adia Med's ongoing efforts to meet Nasdaq's listing standards, though other criter...
Québec Innovative Materials Corp. (QIMC) has started two large-scale, non-invasive 2D seismic surveys totaling about 78 line-kilometres to explore natural hydrogen in Québec and Nova Scotia. The 36 km survey in Québec is in partnership with the Témis...
